Bio Blast Pharma Stock Price | ENLV Stock Quote, News, and History
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
Total Analysts: 6
Buy Ratings: 6 Neutral Ratings: 0 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 12.00 Median: 14.50 Highest: 15.00
- All
- Buy
- Hold
- Sell
| 2024 | |
|---|---|
| Revenue | - |
| Dividend | - |
| Dividend Yield (in %) | - |
| EPS | -0.86 |
| P/E Ratio | -3.34 |
| EBIT | 16 |
| EBITDA | - |
| Net Profit | -16 |
| Net Profit Adjusted | - |
| Pre-Tax Profit | 16 |
| Net Profit (Adjusted) | - |
| EPS (Non-GAAP) ex. SOE | - |
| EPS (GAAP) | - |
| Gross Income | - |
| Cash Flow from Investing | - |
| Cash Flow from Operations | - |
| Cash Flow from Financing | - |
| Cash Flow per Share | - |
| Free Cash Flow | - |
| Free Cash Flow per Share | - |
| Book Value per Share | - |
| Net Debt | - |
| Research & Development Exp. | 12 |
| Capital Expenditure | - |
| Selling, General & Admin. Exp. | - |
| Shareholder’s Equity | - |
| Total Assets | - |
| Previous Quarter | Current Quarter | Next Quarter | Current Year | Next Year | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 1 | - | 1 | - |
| Average Estimate | - | -0.210 USD | - | -0.860 USD | - |
| Year Ago | - | - | - | - | - |
| Publish Date | - | 5/24/2024 | - | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | - | - | - | - |
| Average Estimate | - | - | - | - | - |
| Year Ago | - | - | - | - | - |
| Publish Date | - | - | - | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
*Yield of the Respective Date
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
Risk- Low
- Medium
- High
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.
| Owner | in % |
|---|---|
| Freefloat | 80.56 |
| Kip Global Pharma Ecosystem Private Equity Fund | 7.63 |
| Hadasit Bio-Holdings Ltd. /Private Equity/ | 5.41 |
| Shai A. Novik, MBA | 4.05 |
| ARK Investment Management LLC | 1.78 |
| Dror Mevorach, MD | 1.26 |
| Avri Havron | 0.96 |
| ARK Israel Innovative Technology ETF | 0.61 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
